DYAI — Dyadic International, Inc.

Summary of Dyadic International, Inc. Q4 2025 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.09 million for FY 2025, down from $3.5 million in 2024, primarily due to reduced R&D collaboration activity and lower license/milestone revenue.
• Grant Revenue: Increased by $1.86 million, largely from the Gates Foundation and CEPI.
• Cost of R&D Revenue: Declined to $600,000 from $1.2 million in 2024.
• Internal R&D Expenses: Increased slightly to $2.16 million from $2.04 million.
• G&A Expenses: Decreased to $5.76 million from $6.13 million.
• Loss from Operations: Increased to $7.19 million from $5.9 million in 2024.
• Net Loss: $7.36 million ($0.23 per share) compared to a net loss of $5.81 million ($0.20 per share) in 2024.
• Cash Position: Approximately $8.6 million in cash and equivalents at year-end, with net cash used in operating activities around $5.7 million.

2. Strategic Updates and Business Highlights

• Transitioning from a development-stage company to a commercial, product-driven biotechnology business.
• Rebranding to Dyadic Applied Biosolutions and strengthening technological capabilities through CRISPR licensing.
• Secured manufacturing partnerships, notably with Fermox, and launched commercial products, including recombinant human albumin.
• Established distribution agreements to enhance market penetration for animal-free recombinant proteins.
• Advanced product portfolio in life sciences, food and nutrition, and bioindustrial segments, focusing on sustainable, animal-free proteins.

3. Forward Guidance and Outlook

• Expect disciplined cash usage while prioritizing impactful R&D and grant-funded activities.
• Anticipate growth in product revenues across life sciences and food/nutrition markets, driven by new product launches.
• Project increasing repeat orders and revenue growth through 2026 and beyond, with a focus on scaling product sales and expanding partnerships.

4. Bad News, Challenges, or Points of Concern

• Declining total revenue and increased operational losses indicate ongoing financial challenges during the transition phase.
• The company is still in a transition phase, with current financials not fully reflecting the underlying business advancements.
• The need for additional capital resources and potential dilution concerns due to the establishment of an ATM facility for opportunistic capital access.
• Competitive pressures in pricing and market adoption of new products, particularly in cost-sensitive markets like cultivated meat.

5. Notable Q&A Insights

• Management expects a slow ramp-up in product revenues as companies adapt to new products, with a focus on establishing distribution agreements for larger volume opportunities.
• The timing and structure of new collaborations may vary, with a push for upfront fees depending on product maturity.
• Regulatory scrutiny and market dynamics are influencing the food and nutrition segment, with a shift towards animal-free proteins.
• Discussions on the potential for seasonal vaccines in biopharmaceutical programs, indicating a broader market opportunity beyond pandemic preparedness.
• The company is optimistic about achieving breakeven but acknowledges the uncertainty in timing, emphasizing the importance of product commercialization and market penetration.

Overall, Dyadic International, Inc. is making significant strides towards commercialization, although it faces financial challenges and competitive pressures as it transitions to a product-driven business model.